Testosterone undecanoate depot injection

Drug Profile

Testosterone undecanoate depot injection

Alternative Names: Aveed; Nebido; Reandron

Latest Information Update: 15 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals; Endo Pharmaceuticals Solutions; Sheffield Teaching Hospitals NHS Foundation Trust
  • Class Anabolic steroids; Androstenols; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Testosterone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypogonadism
  • Phase II Non-alcoholic steatohepatitis

Most Recent Events

  • 30 Jan 2017 Sheffield Teaching Hospitals NHS Foundation Trust and Bayer complete the phase II TEREPINS trial in Non-alcoholic steatohepatitis in United Kingdom (NCT01919294)
  • 25 Mar 2014 Launched prior to this date for Hypogonadism in Azerbaijan (IM)
  • 25 Mar 2014 Launched prior to this date for Hypogonadism in Cambodia (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top